SAB Biotherapeutics Appoints Michael G. King Jr. as Chief Financial Officer
Finance leader joins SAB with more than 25 years of experience as a leading biotech equity research analyst
SIOUX FALLS, S.D., Oct. 24, 2023 (GLOBE NEWSWIRE) — SAB Biotherapeutics, Inc. (Nasdaq: SABS), today announced that Michael G. King Jr. has been named Chief Financial Officer. SAB is a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a fully-human anti-thymocyte immunoglobulin (hIgG) that may delay the onset or progression of type 1 diabetes (T1D). Mr. King has extensive experience and prior success as an award-winning biotechnology research analyst and senior advisor with more than 25 years of experience with investors, banking institutions and thought leaders in various pharmaceutical disciplines. Mr. King, who starts his new role on Oct. 30, replaces Russell Beyer, who is expected to step down on Nov. 15 and remain a senior advisor with the company through the end of the year.
Mr. King’s record of achievement includes successful engagements with Hambrecht & Quist, Alex Brown & Sons, Robertson Stephens, Vector Securities, Bank of America, Rodman & Renshaw, JMP Securities, and HC Wainwright. Most recently, he was Co-Head of Healthcare Research at EF Hutton Group. Mr. King received his BA in Finance from the Bernard M. Baruch College of the City University of New York.
“Mike has an outstanding track record of best-in-class relationships in the investment community and is a sought-after advisor for companies seeking strong value creation,” said Eddie J. Sullivan, Ph.D., co-founder, President, and Chief Executive Officer of SAB Biotherapeutics. “I’m confident Mike will help us deliver growth and shareholder value on our path toward creating groundbreaking, disease-modifying treatments that can slow the progression of an autoimmune disease like type 1 diabetes. We remain grateful for the strong contributions of Russell Beyer and wish him the very best in his next venture.”
SAB Executive Chairman Samuel J. Reich notes of the appointment, “SAB is poised to build something transformative in the coming years, and I look forward to Mike’s additions as we advance. I thank Russ for the outstanding service to SAB over the past two years. He’s been a wonderful colleague and the Board wishes him great success in his future endeavors.”
Mr. King said, “It’s an exciting time to work for SAB. The company has a bright future ahead as we work to address unmet patient need in type 1 diabetes. I look forward to working alongside this accomplished management team and Board of Directors to improve our efficiency and deliver shareholder value as we advance clinical trials on the path toward commercialization.”
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics (SAB) is a clinical-stage biopharmaceutical company focused on developing fully human, multi- targeted, high-potency immunoglobulins (IgGs), without the need for human donors or convalescent plasma, to treat and prevent immune and autoimmune disorders. The company’s lead asset, SAB-142, targets type 1 diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the treatment paradigm by delaying onset and potentially preventing disease progression. Using advanced genetic engineering and antibody science to develop Transchromosomic (Tc) Bovine™, the only transgenic animal with a human artificial chromosome, SAB’s DiversitAb™ drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, fully-human IgGs that can address a wide range of serious unmet needs in human diseases without the need for convalescent plasma or human donors. For more information on SAB, visit: https://www.SAb.bio/ and follow SAB on Twitter and LinkedIn.
Forward-Looking Statements
Certain statements made herein that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “to be,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding future events, including the development and efficacy of our T1D program, and other discovery programs.
These statements are based on the current expectations of SAB and are not predictions of actual performance, and are not intended to serve as, and must not be relied on, by any investor as a guarantee, prediction, definitive statement, or an assurance, of fact or probability. These statements are only current predictions or expectations, and are subject to known and unknown risks, uncertainties and other factors which may be beyond our control. Actual events and circumstances are difficult or impossible to predict, and these risks and uncertainties may cause our or our industry’s results, performance, or achievements to be materially different from those anticipated by these forward-looking statements. A further description of risks and uncertainties can be found in the sections captioned “Risk Factors” in our most recent annual report on Form 10-K, as amended, subsequent quarterly reports on Form 10-Q, as may be amended or supplemented from time to time, and other filings with or submissions to, the U.S. Securities and Exchange Commission, which are available at https://www.sec.gov/. Except as otherwise required by law, SAB disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events, or circumstances or otherwise.
Media Relations:
SABPR@westwicke.com
Investor Relations:
matt@milestone-advisorsllc.com
